Prime Medicine Announces Upcoming Conference Participation
Prime Medicine, Inc. (NASDAQ: PRME), a pioneering biotechnology company, has recently made an exciting announcement regarding its participation in several prestigious investor conferences. This initiative highlights the company’s commitment to engaging with the investment community and providing insights into its groundbreaking work in genetic therapies.
Key Conferences to Note
Citi's 2025 Biopharma Back to School Conference
The management team at Prime Medicine will be present for a fireside chat at Citi's 2025 Biopharma Back to School Conference. This event is scheduled for Tuesday, September 2, 2025, at 4:45 p.m. ET, taking place in a vibrant venue in Boston. This conference serves as a platform for discussing crucial developments in the biopharmaceutical sector.
Morgan Stanley's Annual Global Healthcare Conference
Following the Citi event, Prime Medicine will also partake in Morgan Stanley's 23rd Annual Global Healthcare Conference. A fireside chat is scheduled for Monday, September 8, 2025, at 1:05 p.m. ET in New York City. Here, executives will share insights about the company’s progress and future plans, making it a must-attend for investors.
Accessing Company Presentations
For those unable to attend in person, live audio webcasts of each presentation will be available. You can access them by visiting the "Events & Presentations" section on the Prime Medicine website. Replays will be provided for a period of 90 days, ensuring that investors and interested parties can stay informed about the company's latest developments.
About Prime Medicine
Prime Medicine is dedicated to developing a new era of genetic therapies that aim to address numerous genetic disorders. Utilizing the innovative Prime Editing platform, the company is committed to achieving precise and effective gene edits while ensuring minimal unintentional impacts on the DNA. This technology holds immense promise for treating a wide range of genetic conditions across various tissues and organs.
Research and Development Focus
The company is advancing a diverse portfolio of therapeutic programs focusing on liver diseases, lung disorders, and both immunology and oncology. Each program targets diseases with clear biological pathways, providing a strategic route for clinical development. As the company progresses, it aims to broaden its reach, exploring additional genetic disorders, cancers, infectious diseases, and even targeting risk factors in common diseases, potentially impacting millions.
Investor and Media Contacts
Gregory Dearborn
Prime Medicine
Phone: 857-209-0696
Email: gdearborn@primemedicine.com
Hannah Deresiewicz
Precision AQ
Phone: 212-362-1200
Email: hannah.deresiewicz@precisionaq.com
Frequently Asked Questions
What is Prime Medicine?
Prime Medicine, Inc. is a biotechnology firm focused on creating advanced gene editing therapies to treat various genetic conditions.
What are the key upcoming conferences for Prime Medicine?
Prime Medicine will participate in Citi's 2025 Biopharma Back to School Conference and Morgan Stanley's Annual Global Healthcare Conference.
How can I listen to the company presentations?
Live audio webcasts of each presentation will be available on the Prime Medicine website, along with replay access for 90 days post-event.
What is the Prime Editing platform?
The Prime Editing platform is an advanced gene editing technology that allows for precise modifications to DNA with minimal unintended changes, offering a new hope for various genetic disorders.
Who can I contact for more information about Prime Medicine?
For inquiries, you can contact Gregory Dearborn at Prime Medicine or Hannah Deresiewicz at Precision AQ via their provided emails.